Haskill S, Koren H, Becker S, Fowler W, Walton L
Br J Cancer. 1982 May;45(5):747-53. doi: 10.1038/bjc.1982.116.
Macrophages have been isolated from ascitic and collagenase-dispersed tumours from patients undergoing surgery for ovarian cancer. Macrophages were present in varying proportions in both sites, though the ration of macrophages to tumour cells was higher in ascites. Marked variation in size (as detected by sedimentation velocity) and cytochemical markers in the macrophages was noted. Highly enriched macrophage fractions were isolated from the ascites and collagenase-dispersed solid tumours by a combination of sedimentation velocity and selective EA RFC or adherence techniques. Suppressor activity in the PHA assay was detected in tumour macrophages (4/10 giving less than 50% inhibition), ascitic macrophages (1/15) and blood monocytes (2/7). Lymphocyte fractions from tumours were unresponsive to PHA and failed to suppress the blood response. Suppressor activity was also present in the purified tumour-cell fraction of 6/14 patients. ADCC activity was tested in a few patients. When the activity was determined against the SB target cells, tumour-derived macrophages were inactive, whereas the ascitic fraction showed low but significant activity which averaged much lower than patients blood values. The ADCC assays carried out with the CRC target cell indicated activity within the range of patient blood values in 4/4 ascites and 2/4 tumour macrophage fractions. Cytotoxicity was also assessed against co-purified autologous tumour cells. Although activity was detected in many of the tests, the results seemed to reflect target cell sensitivity. There appeared to be a correlation between cytotoxicity with test macrophages and normal blood mononuclear cells. The results indicate that the cytochemical heterogeneity and the variation in size between macrophage fractions is associated with a spectrum of activities.
已从接受卵巢癌手术患者的腹水及经胶原酶分散处理的肿瘤中分离出巨噬细胞。巨噬细胞在这两个部位均以不同比例存在,不过腹水中巨噬细胞与肿瘤细胞的比例更高。注意到巨噬细胞在大小(通过沉降速度检测)和细胞化学标记方面存在显著差异。通过沉降速度与选择性EA RFC或黏附技术相结合,从腹水及经胶原酶分散处理的实体肿瘤中分离出高度富集的巨噬细胞组分。在PHA检测中,肿瘤巨噬细胞(4/10产生低于50%的抑制作用)、腹水巨噬细胞(1/15)及血液单核细胞(2/7)检测到抑制活性。肿瘤淋巴细胞组分对PHA无反应,且无法抑制血液反应。6/14例患者的纯化肿瘤细胞组分中也存在抑制活性。对少数患者进行了ADCC活性检测。当针对SB靶细胞测定活性时,肿瘤来源的巨噬细胞无活性,而腹水组分显示出低但显著的活性,其平均值远低于患者血液值。用CRC靶细胞进行的ADCC检测表明,4/4腹水和2/4肿瘤巨噬细胞组分的活性在患者血液值范围内。还评估了对共纯化的自体肿瘤细胞的细胞毒性。尽管在许多检测中检测到活性,但结果似乎反映了靶细胞的敏感性。测试巨噬细胞的细胞毒性与正常血液单核细胞之间似乎存在相关性。结果表明,巨噬细胞组分之间的细胞化学异质性和大小差异与一系列活性相关。